% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • redhot47fla redhot47fla Apr 9, 2013 1:08 PM Flag

    SGN-LIV1A for breast cancer: Is this new news? (It sounds new to me.)

    From today's press release: In addition, preclinical data demonstrate activity of a new ADC for metastatic breast cancer, SGN-LIV1A, utilizing the same proprietary ADC technology as ADCETRIS® (brentuximab vedotin)....

    SGN-LIV1A is an ADC that targets LIV-1, which is expressed in most subtypes of metastatic breast cancer. Preclinical data demonstrated that up to 92 percent of breast tumors analyzed expressed LIV-1, while expression was limited in normal tissue. SGN-LIV1A is comprised of an anti-LIV-1 monoclonal antibody linked to a synthetic cell-killing agent called monomethyl auristatin E (MMAE). SGN-LIV1A demonstrated significant antitumor activity in multiple preclinical models at well-tolerated doses. Seattle Genetics plans to submit an IND and initiate a phase 1clinical trial of SGN-LIV1A for breast cancer in 2013. (Abstract 3962)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
55.71-0.12(-0.21%)Sep 26 4:00 PMEDT